

**Food and Drug Administration  
Center for Drug Evaluation and Research**

**Advisory Committee for Pharmaceutical Science**

**October 21-22, 2003**

Best Western Washington Gateway Hotel  
1251 West Montgomery Avenue  
Rockville, MD 20857

**Agenda**

**Day 1: Tuesday, October 21, 2003**

8:30	<b>Call to Order and Opening Remarks</b>	Art Kibbe, Ph.D. Chair, ACPS
	<b>Introduction of Committee</b>	
	<b>Conflict of Interest Statement</b>	Hilda F. Scharen, M.S. Executive Secretary, ACPS
8:45	<b>Introduction</b>	Helen Winkle Director, Office of Pharmaceutical Science, CDER, FDA
	<b><i>Subcommittee Reports</i></b>	
9:00	<b>Manufacturing</b>	Judy Boehlert, Ph.D. Chair, Manufacturing Subcommittee
	<b>Clinical Pharmacology</b>	Jürgen Venitz, M.D., Ph.D. Chair, Clinical Pharmacology Subcommittee
	<b><i>Draft PAT Guidance</i></b>	
10:00	<b>Update</b>	Ajaz Hussain, Ph.D. Deputy Director, Office of Pharmaceutical Science, CDER, FDA
	<b>Questions/Discussion</b>	
10:30	Break	
	<b><i>Parametric Tolerance Interval Test for Dose Content Uniformity</i></b>	
10:45	<b>Overview and Issues</b>	Ajaz Hussain, Ph.D. Deputy Director, Office of Pharmaceutical Science, CDER, FDA
11:30	<b>Open Public Hearing</b>	
12:30	<b>Lunch</b>	
1:30	<b>Approaches for resolving identified issues</b>	
	<b>IPAC-RS Presentations</b>	
2:30	Break	
2:45	<b>Committee Discussion and Recommendations</b>	
4:30	<b>Adjourn</b>	

Center for Drug Evaluation and Research

Advisory Committee for Pharmaceutical Science

October 21-22, 2003

Best Western Washington Gateway Hotel  
1251 West Montgomery Avenue  
Rockville, MD 20857

**Agenda**

**Day 2: Wednesday, October 22, 2003**

- |       |  |  |
|-------|--|--|
| 8:30  | <b>Call to Order and Opening Remarks</b>             | Art Kibbe, Ph.D.<br>Chair, ACPS  |
|       | <b>Introduction of Committee</b>                     |  |
|       | <b>Conflict of Interest Statement</b>                | Hilda F. Scharen, M.S.<br>Executive Secretary, ACPS                                    |
|       | <br><i>Risk-based CMC Review Proposals</i>           |  |
| 8:45  | <b>Current Thinking</b>                              |  |
|       | <b>Focus on “process understanding”</b>              | Ajaz Hussain, Ph.D.<br>Deputy Director, Office of Pharmaceutical<br>Science, CDER, FDA |
|       | <b>Issues and challenges</b>                         |  |
|       | <b>Committee Discussion</b>                          |  |
| 10:15 | <b>Break</b>   |  |
|       | <br><i>Nomenclature</i>                              |  |
| 10:45 | <b>Proposals for resolving issues and challenges</b> |  |
|       | <b>FDA Perspective</b>                               |  |
|       | <b>Committee Discussion</b>                          |  |
| 12:00 | <b>Lunch</b>   |  |
| 1:00  | <b>Open Public Hearing</b>                           |  |

Center for Drug Evaluation and Research

**Advisory Committee for Pharmaceutical Science**

**October 21-22, 2003**

Best Western Washington Gateway Hotel  
1251 West Montgomery Avenue  
Rockville, MD 20857

**Agenda**

**Day 2: Wednesday, October 22, 2003 (Cont'd)**

***Research Plan for Generics – Bioequivalence of Topical Products***

2:00 **Generic Drug Research Program**

**Dermatopharmacokinetics: Improvement of methodology for assessing bioequivalence of topical products**

**Bioequivalence of topical products: FDA Perspective**

3:00 **Break**

3:15 **Committee Discussion**

4:45 **Conclusion and Summary Remarks**

Ajaz Hussain, Ph.D.  
Deputy Director, Office of Pharmaceutical  
Science, CDER, FDA

5:00 **Adjourn**